Loading...
Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
Ghosal, N Mais, Kathleen L Shenjere, Patrick Julyan, Peter J Hastings, David L Ward, Timothy H Ryder, W David J Bruce, I Homer, Jarrod J Slevin, Nicholas J
Ghosal, N
Mais, Kathleen L
Shenjere, Patrick
Julyan, Peter J
Hastings, David L
Ward, Timothy H
Ryder, W David J
Bruce, I
Homer, Jarrod J
Slevin, Nicholas J
Citations
Altmetric:
Abstract
Patients with adenoid cystic carcinoma of the salivary glands show over-expression of KIT in a high proportion of cases. Options for systemic treatment are limited in locally advanced and metastatic disease. We explored the efficacy of imatinib and cisplatin combined in this group of patients. A Gehan's two-stage, phase II trial was conducted on 28 patients. Those with progressive, locally advanced, and metastatic disease with an over-expression of KIT were treated with single agent imatinib 800 mg daily for two months, followed by a combination of imatinib 400mg daily and cisplatin 80 mg/m(2) at four-weekly intervals for six cycles. This was followed by maintenance single agent imatinib 400mg daily until the disease progressed. Response was monitored using fluorodeoxyglucose positron emission tomography (FDG-PET) and morphological imaging using computed tomography, magnetic resonance, and chest radiographs (CT/MRI/CXR). Morphological imaging showed partial response in three of 28 patients, and five patients showed a response on FDG-PET. In addition, 19 patients had useful stabilisation of disease. The median time to progression and overall survival was 15 months (range 1-43) and 35 months (range 1-75), respectively. The combination of imatinib and cisplatin was reasonably well tolerated. This combination may provide stabilisation in locally advanced and metastatic adenoid cystic carcinoma of the salivary glands.
Description
Date
2011-10
Publisher
Keywords
Type
Article
Citation
Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. 2011, 49 (7):510-5 Br J Oral Maxillofac Surg